Novo Nordisk’s Weight-loss Drug Wegovy Set to Enter Chinese Market
Novo Nordisk, one of the leading pharmaceutical companies, is gearing up for the approval of its weight-loss drug Wegovy in China later this year. Wegovy, also known as semaglutide, is a type of GLP-1 drug that is commonly used to treat obesity and diabetes.
The company’s strategy for the launch in China will primarily target patients who are willing to pay for the drug out-of-pocket. This move comes as several drugmakers are currently conducting clinical trials for generic versions of GLP-1 drugs, but none are expected to be approved before 2028.
The patent for Wegovy in China is set to expire in 2026, which could potentially open the door for generic versions of the drug to enter the market. However, Novo Nordisk remains optimistic about the successful entry of Wegovy in China.
Novo Nordisk faces stiff competition in the GLP-1 drug field, with Eli Lilly being its main rival. Eli Lilly markets its own versions of GLP-1 drugs under the brand names Mounjaro and Zepbound. Additionally, other pharmaceutical companies such as AstraZeneca, Amgen, Pfizer, Viking Therapeutics, Tern Pharmaceuticals, and Structure Therapeutics are also developing GLP-1 drugs.
With the impending approval of Wegovy in China, Novo Nordisk aims to solidify its position in the competitive market for weight-loss and diabetes medications. Stay tuned for more updates on this groundbreaking development from Jala News.
“Infuriatingly humble tv expert. Friendly student. Travel fanatic. Bacon fan. Unable to type with boxing gloves on.”